Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CDKN2A_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CDKN2A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CDKN2A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDKN2A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CDKN2A_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDKN2A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CDKN2A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CDKN2A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDKN2A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CDKN2A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDKN2A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075688 | Breast | Precancer | aging | 41/1080 | 339/18723 | 5.95e-06 | 1.71e-04 | 41 |
GO:00160497 | Breast | Precancer | cell growth | 46/1080 | 482/18723 | 5.63e-04 | 7.16e-03 | 46 |
GO:00075694 | Breast | Precancer | cell aging | 17/1080 | 132/18723 | 1.55e-03 | 1.59e-02 | 17 |
GO:00015587 | Breast | Precancer | regulation of cell growth | 39/1080 | 414/18723 | 1.81e-03 | 1.78e-02 | 39 |
GO:00903423 | Breast | Precancer | regulation of cell aging | 10/1080 | 61/18723 | 2.40e-03 | 2.21e-02 | 10 |
GO:00513489 | Breast | Precancer | negative regulation of transferase activity | 27/1080 | 268/18723 | 3.49e-03 | 2.90e-02 | 27 |
GO:0033028 | Breast | Precancer | myeloid cell apoptotic process | 6/1080 | 29/18723 | 5.49e-03 | 4.01e-02 | 6 |
GO:0006925 | Breast | Precancer | inflammatory cell apoptotic process | 5/1080 | 21/18723 | 5.93e-03 | 4.21e-02 | 5 |
GO:2000106 | Breast | Precancer | regulation of leukocyte apoptotic process | 11/1080 | 81/18723 | 6.65e-03 | 4.57e-02 | 11 |
GO:000756813 | Breast | IDC | aging | 52/1434 | 339/18723 | 1.14e-06 | 5.10e-05 | 52 |
GO:005134814 | Breast | IDC | negative regulation of transferase activity | 39/1434 | 268/18723 | 7.89e-05 | 1.56e-03 | 39 |
GO:00459369 | Breast | IDC | negative regulation of phosphate metabolic process | 53/1434 | 441/18723 | 7.21e-04 | 8.79e-03 | 53 |
GO:00105639 | Breast | IDC | negative regulation of phosphorus metabolic process | 53/1434 | 442/18723 | 7.60e-04 | 9.25e-03 | 53 |
GO:001604913 | Breast | IDC | cell growth | 56/1434 | 482/18723 | 1.16e-03 | 1.26e-02 | 56 |
GO:000155813 | Breast | IDC | regulation of cell growth | 49/1434 | 414/18723 | 1.55e-03 | 1.55e-02 | 49 |
GO:00071625 | Breast | IDC | negative regulation of cell adhesion | 37/1434 | 303/18723 | 3.27e-03 | 2.75e-02 | 37 |
GO:000756912 | Breast | IDC | cell aging | 19/1434 | 132/18723 | 5.63e-03 | 4.08e-02 | 19 |
GO:00108109 | Breast | IDC | regulation of cell-substrate adhesion | 28/1434 | 221/18723 | 5.88e-03 | 4.24e-02 | 28 |
GO:00903421 | Breast | IDC | regulation of cell aging | 11/1434 | 61/18723 | 6.10e-03 | 4.36e-02 | 11 |
GO:00064699 | Breast | IDC | negative regulation of protein kinase activity | 27/1434 | 212/18723 | 6.30e-03 | 4.47e-02 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDKN2A | SNV | Missense_Mutation | novel | c.357N>T | p.Glu119Asp | p.E119D | P42771 | protein_coding | tolerated(0.44) | benign(0.153) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDKN2A | deletion | Frame_Shift_Del | | c.407delN | p.Gly136AlafsTer10 | p.G136Afs*10 | P42771 | protein_coding | | | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
CDKN2A | insertion | Frame_Shift_Ins | novel | c.130_131insT | p.Tyr44LeufsTer76 | p.Y44Lfs*76 | P42771 | protein_coding | | | TCGA-EY-A1GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
CDKN2A | SNV | Missense_Mutation | | c.257C>A | p.Ala86Asp | p.A86D | P42771 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DD-AAC9-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CDKN2A | SNV | Missense_Mutation | | c.323A>G | p.Asp108Gly | p.D108G | P42771 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DD-AACK-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CDKN2A | SNV | Missense_Mutation | rs11552822 | c.250G>T | p.Asp84Tyr | p.D84Y | P42771 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DD-AAD6-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
CDKN2A | SNV | Missense_Mutation | rs771138120 | c.168N>A | p.Ser56Arg | p.S56R | P42771 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-DD-AAW3-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CDKN2A | SNV | Missense_Mutation | | c.247C>G | p.His83Asp | p.H83D | P42771 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-ED-A7XP-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CDKN2A | SNV | Missense_Mutation | rs121913381 | c.322N>T | p.Asp108Tyr | p.D108Y | P42771 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G3-AAV0-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CDKN2A | insertion | Frame_Shift_Ins | novel | c.50_51insTGGC | p.Thr18GlyfsTer27 | p.T18Gfs*27 | P42771 | protein_coding | | | TCGA-DD-AAD8-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | ON-01910 | RIGOSERTIB | 25156567 |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | LY2835219 | ABEMACICLIB | |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | Alvocidib | ALVOCIDIB | 12777976 |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | Palbociclib | PALBOCICLIB | |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | BAY1000394 | | |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | LETROZOLE | LETROZOLE | 26715889 |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | VEMURAFENIB | VEMURAFENIB | 24265155 |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | PD 0332991 | | |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | ZK304709 | | 18829975 |
1029 | CDKN2A | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE, TUMOR SUPPRESSOR | | Sapanisertib | SAPANISERTIB | 25261369 |